1-5 of 5
Andreas Engert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial

Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Helen Goergen, Horst Müller, Christian Baues, Ulrich Keller, Julia Meissner, Karolin Trautmann-Grill, Andrea Kerkhoff, Michael Fuchs, Stephanie Sasse, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert, Carsten Kobe, Paul J. Bröckelmann
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 402–407.
https://doi.org/10.1158/1078-0432.CCR-20-3303
Published: 19 January 2021
View article titled, Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Open the PDF for Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial in another window
Journal Articles

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Bastian von Tresckow, Franck Morschhauser, Vincent Ribrag, Max S. Topp, Caly Chien, Shobha Seetharam, Regina Aquino, Sonja Kotoulek, Carla J. de Boer, Andreas Engert
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (8): 1843–1850.
https://doi.org/10.1158/1078-0432.CCR-14-1845
Published: 14 April 2015
View article titled, An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Open the PDF for An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Prognostic Serum Cytokines in Classical Hodgkin Lymphoma—Letter

Oliver Coutelle, Hildegard Büning, Annette Plütschow, Michael Fuchs, Laura Escalona-Espinosa, Andreas Engert, Ulrich Hacker
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6633.
https://doi.org/10.1158/1078-0432.CCR-14-1735
Published: 14 December 2014
View article titled, Prognostic Serum Cytokines in Classical Hodgkin Lymphoma—Letter
Open the PDF for Prognostic Serum Cytokines in Classical Hodgkin Lymphoma—Letter in another window
Journal Articles

Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity

Boris Böll, Farag Eltaib, Katrin S. Reiners, Bastian von Tresckow, Samir Tawadros, Venkateswara R. Simhadri, Francis J. Burrows, Karen Lundgren, Hinrich P. Hansen, Andreas Engert, Elke Pogge von Strandmann
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5108–5116.
https://doi.org/10.1158/1078-0432.CCR-09-0213
Published: 12 August 2009
View article titled, Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity
Open the PDF for Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity in another window
Journal Articles

A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin’s and Non-Hodgkin’s Lymphoma

Roland Schnell, Oliver Staak, Peter Borchmann, Christine Schwartz, Bärbel Matthey, Hinrich Hansen, John Schindler, Victor Ghetie, Ellen S. Vitetta, Volker Diehl, Andreas Engert
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (6): 1779–1786.
Published: 01 June 2002
View article titled, A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30<sup>+</sup> Hodgkin’s and Non-Hodgkin’s Lymphoma
Open the PDF for A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30<sup>+</sup> Hodgkin’s and Non-Hodgkin’s Lymphoma in another window